Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous
From Cell & Gene: The Podcast · · 40 min
This plays from the publisher's own server. We do not host a copy.
Description
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1810482/fan_mail/new)
On episode 136 of Cell & Gene: The Podcast, Host Erin Harris welcomes back Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath to discuss why autoimmune CAR T is moving rapidly from an emerging concept toward a potentially transformative treatment approach. They talk about the very different benefit-risk calculus in autoimmune disease compared with oncology, the patient and caregiver burden of conditioning, apheresis and long-term monitoring, and the need to rethink clinical trial endpoints around meaningful outcomes. They explore the potential of in vivo CAR T and circular RNA to eliminate some of the biggest barriers in the current treatment pathway, while discussing the scientific and durability questions that remain.
Subscribe to the podcast! Apple (https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063) | Spotify (https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya) | YouTube (https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX)
Visit my website: Cell & Gene (https://www.cellandgene.com/)
Connect with me on LinkedIn (https://www.linkedin.com/in/erinharris/)